🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT05776277
Active, not recruiting Phase 3

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

NCT05776277 · tracked via the Priya Life Science USA tracker
Sponsor
Cook MyoSite
Phase
Phase 3
Started
2024-03-21
Last updated
2026-07-21

Condition(s) studied

Fecal Incontinence

Investigational drug(s) / intervention(s)

IltamiocelPlacebo

Iltamiocel: Single external anal sphincter (EAS) injection of 300 x 10\^6 cells.

Placebo: Placebo control is the vehicle solution used for the study product.

Study summary

This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10\^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Adult female ≥ 18 years of age who has primary symptoms of fecal incontinence (FI) for at least 12 months. * History of obstetric anal sphincter injury (e.g., episiotomy, perineal tear). * Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment. * Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures. Exclusion Criteria: * Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician. * Is pregnant or planning to become pregnant within the next 2 years. * Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity). * Has an obstetric anal sphincter injury (e.g., episiotomy, perineal tear) within 1 year previous to study enrollment. * Patient BMI ≥ 38. * Has a history of cancer in the colorectal or pelvic organs within 5 years prior to study enrollment. * Any cancer that has undergone treatment within the past 12 months. * Has an established diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or current intestinal stoma. * Has grade III/IV hemorrhoids. * Has chronic diarrhea at the time of Screening. * Has chronic constipation at the time of Screening. * Has significant pelvic floor prolapse, significant genitourinary prolapse beyond the introitus, significant symptomatic rectocele, or evidence of significant rectal evacuation disorder leading to post-defecatory leakage.

Primary outcome measure(s)

Trial sites (25)

FacilityCityRegionStatus
UC San Diego Health La Jolla California
UC Irvine Medical Center Orange California
University of California, San Francisco - Center for Colorectal Surgery San Francisco California
Prestige Medical Group Tustin California
American Association of Female Pelvic Medicine Westlake Village California
University of Florida Shands Hospital Gainesville Florida
Healthcare Clinical Data, Inc. Miami Florida
Orlando Health Colon & Rectal Institute Orlando Florida
USF Health South Tampa Center for Advanced Healthcare Tampa Florida
Colorectal Wellness Center Fayetteville Georgia
University of Illinois Chicago Illinois
Franciscan Health Indianapolis Indianapolis Indiana
Ochsner Health New Orleans Louisiana
Massachusetts General Hospital Boston Massachusetts
Bennett Institute of Urogynecology and Incontinence Grand Rapids Michigan
University of Minnesota Minneapolis Minnesota
Mayo Clinic Rochester Minnesota
Washington University School of Medicine St Louis Missouri
Rutgers, Robert Wood Johnson Medical School, Clinical Research Center New Brunswick New Jersey
Westchester Medical Center Hawthorne New York
The Mount Sinai Medical Center New York New York
Weill Cornell Medicine New York New York
Stony Brook University Hospital Stony Brook New York
Cleveland Clinic Main Campus Crile Building Cleveland Ohio
Rhode Island Hospital Providence Rhode Island

More Cook MyoSite trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05776277 on ClinicalTrials.gov ↗ ← All trials in the USA